近日，一则关于上海璎黎药业有限公司（以下简称"璎黎药业"）"大门被封"的消息在业内不胫而走。这 家曾因研发出高选择性PI3Kδ抑制剂林普利塞片（商品名：因他瑞，以下简称"林普利塞"）而声名鹊 起，并曾获得恒瑞医药2000万美元战略投资的明星Biotech（生物科技公司），如今却陷入窘境。 针对上述传闻，2月11日，璎黎药业发布声明称，公司所有经营活动均正常有序进行，各项研发、生 产、运营及服务工作均按计划稳步推进，并未出现任何影响公司正常运转的异常情形。 《每日经济新闻》记者（以下简称"每经记者"）实探璎黎药业位于上海漕河泾康桥商务绿洲的注册地址 后发现，公司大门及各处出入口均贴有封条，部分办公室已处于清空状态，现场还有两名工人正在包装 设备仪器等。一名璎黎药业工作人员向记者表示，公司确实正在整体搬迁，主要原因是"和房东有一些 租房上的纠纷，并不是企业经营有什么大的问题"。 此外，也有多位患者向记者反映，林普利塞这款"救命药"自2025年四季度起就已出现断供的情况，在多 地医院和药店均已无法采购，此前药企承诺的赠药活动也成了一张"空头支票"。 2月10日上午，每经记者再次来到璎黎药业办公地点。经由货运电梯来到 ...

Core Viewpoint - Shanghai Yingli Pharmaceutical Co., Ltd. is facing operational challenges, including relocation and supply issues with its key product, Linpulise, which has led to concerns among patients and stakeholders [1][12][14]. Group 1: Company Operations - Yingli Pharmaceutical has announced that all business activities are proceeding normally, with research, production, and operations on schedule despite rumors of operational disruptions [2][12]. - The company is currently undergoing relocation due to disputes with its landlord, not due to significant operational issues [2][9]. - As of the latest reports, the company has around 30 employees remaining at its current location, with some staff involved in packing and moving equipment [3][8]. Group 2: Product Supply Issues - Linpulise, a critical drug for patients, has been in short supply since the fourth quarter of 2025, with reports of unfulfilled patient assistance programs [14][15]. - Patients have expressed difficulties in obtaining Linpulise, which has led to a search for alternative treatments [15][16]. - The drug was previously included in the national medical insurance directory but was removed in the latest update, limiting its market access and increasing its retail price to 11,040 yuan per bottle [17][18]. Group 3: Legal and Financial Challenges - Yingli Pharmaceutical has been involved in over 30 lawsuits since 2025, primarily related to contract disputes with suppliers and service providers [18]. - The company has been ordered to pay approximately 2.25 million yuan due to a legal ruling related to a service contract dispute [18]. - The financial strain from these legal issues and operational challenges has raised concerns about the company's future viability and its ability to meet obligations to suppliers and patients [18]. Group 4: Future Prospects - The future of Yingli Pharmaceutical may hinge on its partnership with Heng Rui Medicine, which has invested in the company and holds commercialization rights for Linpulise [18]. - Heng Rui Medicine has stated that it is actively assisting with related matters and that discussions regarding future cooperation are ongoing [18].

Core Viewpoint - Shanghai Yingli Pharmaceutical Co., Ltd. is facing operational challenges, including relocation due to disputes with the landlord, despite claims of normal business operations [2][21][30]. Group 1: Company Operations - The company has announced that all business activities are proceeding normally, with research, production, and operations on schedule [2][21][32]. - Reports indicate that the company's premises are sealed, and some offices are being cleared, suggesting a significant operational shift [2][22][30]. - Employees have confirmed that the company is relocating to Zhangjiang due to rental disputes, not operational issues [2][28][30]. Group 2: Product Supply Issues - The core product, Linpulise (also known as "因他瑞"), has been in short supply since Q4 2025, affecting patients who rely on it [2][15][34]. - Patients have reported that the promised drug donation programs have not been fulfilled, leading to further distress among those dependent on the medication [15][35][36]. - The drug's price is set at 11,040 yuan per bottle, and its removal from the national medical insurance directory has severely limited its market accessibility [18][37]. Group 3: Financial and Legal Challenges - The company is facing over 30 lawsuits related to various contractual disputes, indicating significant financial strain [18][37]. - A recent court ruling has mandated the company to pay approximately 2.25 million yuan due to a service contract dispute [18][37]. - The reliance on a single product, Linpulise, and the lack of a robust pipeline for new drugs are underlying factors contributing to the company's current difficulties [18][37]. Group 4: Future Prospects - The future of Yingli Pharmaceutical may hinge on the decisions made by its strategic partner, Heng Rui Medicine, regarding the commercialization of Linpulise [19][38]. - Heng Rui Medicine has stated that they are actively assisting with the ongoing issues related to Linpulise and are in discussions about future cooperation [19][38].